PT. Nufarindo (Exeltis Indonesia)

Established April 30th , 1974 with the name of PT. EMPEECO, February 24th,1977, changed to PT. Nusa Jaya Farma Indonesia, then on June 15th,1981 using the name of PT NUFARINDO. In its development, PT NUFARINDO do a lot of innovation and improvement. PT NUFARINDO also been equipped with CGMP to improve Quality Assurance on drugs produced by PT NUFARINDO, as well as to expand the marketing network products internationally. December 10th , 2012 PT. Nufarindo join as a member of Chemo-Group a multinational pharmaceutical company, based in Madrid, Spain. With the merger of PT. Nufarindo to chemo Group, intends to transform a good local company into a leading player in the field of pharmacy products. Senior management team has a good track record, proved to have been successful in managing the company well in the past until the transition period. October 15, 2013 Chemo launched a new brand of pharmaceutical "Exeltis"​. PT Nufarindo as Chemo-Group members, automatically become part of the Global "Exeltis"​. Our ambition is to consistently outperform the market by maintaining full customer focus, with a working environment that allows people to act flexibly within certain limits.

PharmaCare Laboratories

PharmaCare is one of the largest Australian-owned health, wellness and consumer goods companies in the country. An Australian-born and built success story, PharmaCare is dedicated to enriching people’s lives through improved health and wellness. Despite its products being available globally, its soul is Australian, its quality is Australian, and its spirit of honesty, hard work and entrepreneurial drive is Australian. PharmaCare’s trusted, household brands include Sambucol, Nature’s Way, Bioglan, Medi+, Ease-a-Cold, Skin Doctors, KP24, Brut, Norsca, Bounce and many more. Our global wheelhouse of brands is available in 40 countries, over 5,200 pharmacies, 3,000 supermarkets, plus department and variety stores all over Australia, New Zealand, Asia, The America's and Europe.

MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com

Advarra

Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster. For more information, visit advarra.com.

Merz Therapeutics

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.